Pioglitazone may accelerate disease course of slowly progressive type 1 diabetes
Background It has been reported that intervention with insulin in slowly progressive type 1 diabetic (SPIDDM) patients delays the progression to an insulin‐dependent state compared to that with sulfonylureas. However, the rate of progression to SPIDDM with the use of insulin‐sensitizing agents is un...
Gespeichert in:
| Veröffentlicht in: | Diabetes/metabolism research and reviews 2011-11, Vol.27 (8), p.951-953 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 953 |
|---|---|
| container_issue | 8 |
| container_start_page | 951 |
| container_title | Diabetes/metabolism research and reviews |
| container_volume | 27 |
| creator | Shimada, Akira Shigihara, Toshikatsu Okubo, Yoshiaki Katsuki, Takeshi Yamada, Yoshifumi Oikawa, Yoichi |
| description | Background
It has been reported that intervention with insulin in slowly progressive type 1 diabetic (SPIDDM) patients delays the progression to an insulin‐dependent state compared to that with sulfonylureas. However, the rate of progression to SPIDDM with the use of insulin‐sensitizing agents is unknown. The aim of this study was to determine the effect of insulin‐sensitizing agents on SPIDDM patients.
Methods
The enrolled SPIDDM patients were randomly allocated to a pioglitazone or metformin group. When the haemoglobin A1C level was more than 8% on two consecutive occasions, the case was considered to reach the end point.
Results
By 4 years post‐intervention, all patients had reached the end point in the pioglitazone group, whereas only 20% of patients had reached the end point in the metformin group (p < 0.05).
Conclusions
Pioglitazone may accelerate the disease course of SPIDDM. Copyright © 2011 John Wiley & Sons, Ltd. |
| doi_str_mv | 10.1002/dmrr.1235 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_903148493</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>903148493</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4565-51d203ebb0a05961dd396d0a8abdfafe62295aa029991b051f996c350dbf5fbf3</originalsourceid><addsrcrecordid>eNp1kEFPGzEUhC3UClLKgT-AVuoB9bDwbK-98RElDaWEFkVFcLO862e0YTcb7E3p8utxlJBDpZ7mHb4ZzRtCjimcUQB2bhvvzyjjYo8MqGCQ5kLCh90t2AH5FMIcAHgms31ywBhIxRQdkNvbqn2sq868tgtMGtMnpiyxRm86TGwV0ARMynblo7QuCXX7UvfJ0rePHkOo_mDS9UtMaGRNgR2Gz-SjM3XAo60ekrvJt9-j7-n01-XV6GKalpmQIhXUMuBYFGBAKEmt5UpaMENTWGccSsaUMAaYUooWIKhTSpZcgC2ccIXjh-R0kxu7PK8wdLqpQmxemwW2q6AVcJoNM8Uj-eUfch7_WcRymuYyl1QIGEbq64YqfRuCR6eXvmqM7zUFvV5Zr1fW65Uje7JNXBUN2h35PmsEzjfAS1Vj__8kPb6ZzbaR6cZRhQ7_7hzGP2mZ81zo-5-XevpDTsb57EFf8zdHgZY0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1767615508</pqid></control><display><type>article</type><title>Pioglitazone may accelerate disease course of slowly progressive type 1 diabetes</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><creator>Shimada, Akira ; Shigihara, Toshikatsu ; Okubo, Yoshiaki ; Katsuki, Takeshi ; Yamada, Yoshifumi ; Oikawa, Yoichi</creator><creatorcontrib>Shimada, Akira ; Shigihara, Toshikatsu ; Okubo, Yoshiaki ; Katsuki, Takeshi ; Yamada, Yoshifumi ; Oikawa, Yoichi</creatorcontrib><description>Background
It has been reported that intervention with insulin in slowly progressive type 1 diabetic (SPIDDM) patients delays the progression to an insulin‐dependent state compared to that with sulfonylureas. However, the rate of progression to SPIDDM with the use of insulin‐sensitizing agents is unknown. The aim of this study was to determine the effect of insulin‐sensitizing agents on SPIDDM patients.
Methods
The enrolled SPIDDM patients were randomly allocated to a pioglitazone or metformin group. When the haemoglobin A1C level was more than 8% on two consecutive occasions, the case was considered to reach the end point.
Results
By 4 years post‐intervention, all patients had reached the end point in the pioglitazone group, whereas only 20% of patients had reached the end point in the metformin group (p < 0.05).
Conclusions
Pioglitazone may accelerate the disease course of SPIDDM. Copyright © 2011 John Wiley & Sons, Ltd.</description><identifier>ISSN: 1520-7552</identifier><identifier>EISSN: 1520-7560</identifier><identifier>DOI: 10.1002/dmrr.1235</identifier><identifier>PMID: 22069291</identifier><identifier>CODEN: DMRRFM</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>Adult ; Age of Onset ; Diabetes Mellitus, Type 1 - drug therapy ; Disease Progression ; Female ; Glycated Hemoglobin A - metabolism ; Humans ; Hypoglycemic Agents - adverse effects ; Hypoglycemic Agents - therapeutic use ; Male ; metformin ; Metformin - therapeutic use ; Middle Aged ; pioglitazone ; slowly progressive type 1 diabetes ; Thiazolidinediones - adverse effects</subject><ispartof>Diabetes/metabolism research and reviews, 2011-11, Vol.27 (8), p.951-953</ispartof><rights>Copyright © 2011 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4565-51d203ebb0a05961dd396d0a8abdfafe62295aa029991b051f996c350dbf5fbf3</citedby><cites>FETCH-LOGICAL-c4565-51d203ebb0a05961dd396d0a8abdfafe62295aa029991b051f996c350dbf5fbf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fdmrr.1235$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fdmrr.1235$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22069291$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shimada, Akira</creatorcontrib><creatorcontrib>Shigihara, Toshikatsu</creatorcontrib><creatorcontrib>Okubo, Yoshiaki</creatorcontrib><creatorcontrib>Katsuki, Takeshi</creatorcontrib><creatorcontrib>Yamada, Yoshifumi</creatorcontrib><creatorcontrib>Oikawa, Yoichi</creatorcontrib><title>Pioglitazone may accelerate disease course of slowly progressive type 1 diabetes</title><title>Diabetes/metabolism research and reviews</title><addtitle>Diabetes Metab. Res. Rev</addtitle><description>Background
It has been reported that intervention with insulin in slowly progressive type 1 diabetic (SPIDDM) patients delays the progression to an insulin‐dependent state compared to that with sulfonylureas. However, the rate of progression to SPIDDM with the use of insulin‐sensitizing agents is unknown. The aim of this study was to determine the effect of insulin‐sensitizing agents on SPIDDM patients.
Methods
The enrolled SPIDDM patients were randomly allocated to a pioglitazone or metformin group. When the haemoglobin A1C level was more than 8% on two consecutive occasions, the case was considered to reach the end point.
Results
By 4 years post‐intervention, all patients had reached the end point in the pioglitazone group, whereas only 20% of patients had reached the end point in the metformin group (p < 0.05).
Conclusions
Pioglitazone may accelerate the disease course of SPIDDM. Copyright © 2011 John Wiley & Sons, Ltd.</description><subject>Adult</subject><subject>Age of Onset</subject><subject>Diabetes Mellitus, Type 1 - drug therapy</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Glycated Hemoglobin A - metabolism</subject><subject>Humans</subject><subject>Hypoglycemic Agents - adverse effects</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Male</subject><subject>metformin</subject><subject>Metformin - therapeutic use</subject><subject>Middle Aged</subject><subject>pioglitazone</subject><subject>slowly progressive type 1 diabetes</subject><subject>Thiazolidinediones - adverse effects</subject><issn>1520-7552</issn><issn>1520-7560</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kEFPGzEUhC3UClLKgT-AVuoB9bDwbK-98RElDaWEFkVFcLO862e0YTcb7E3p8utxlJBDpZ7mHb4ZzRtCjimcUQB2bhvvzyjjYo8MqGCQ5kLCh90t2AH5FMIcAHgms31ywBhIxRQdkNvbqn2sq868tgtMGtMnpiyxRm86TGwV0ARMynblo7QuCXX7UvfJ0rePHkOo_mDS9UtMaGRNgR2Gz-SjM3XAo60ekrvJt9-j7-n01-XV6GKalpmQIhXUMuBYFGBAKEmt5UpaMENTWGccSsaUMAaYUooWIKhTSpZcgC2ccIXjh-R0kxu7PK8wdLqpQmxemwW2q6AVcJoNM8Uj-eUfch7_WcRymuYyl1QIGEbq64YqfRuCR6eXvmqM7zUFvV5Zr1fW65Uje7JNXBUN2h35PmsEzjfAS1Vj__8kPb6ZzbaR6cZRhQ7_7hzGP2mZ81zo-5-XevpDTsb57EFf8zdHgZY0</recordid><startdate>201111</startdate><enddate>201111</enddate><creator>Shimada, Akira</creator><creator>Shigihara, Toshikatsu</creator><creator>Okubo, Yoshiaki</creator><creator>Katsuki, Takeshi</creator><creator>Yamada, Yoshifumi</creator><creator>Oikawa, Yoichi</creator><general>John Wiley & Sons, Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201111</creationdate><title>Pioglitazone may accelerate disease course of slowly progressive type 1 diabetes</title><author>Shimada, Akira ; Shigihara, Toshikatsu ; Okubo, Yoshiaki ; Katsuki, Takeshi ; Yamada, Yoshifumi ; Oikawa, Yoichi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4565-51d203ebb0a05961dd396d0a8abdfafe62295aa029991b051f996c350dbf5fbf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Age of Onset</topic><topic>Diabetes Mellitus, Type 1 - drug therapy</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Glycated Hemoglobin A - metabolism</topic><topic>Humans</topic><topic>Hypoglycemic Agents - adverse effects</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Male</topic><topic>metformin</topic><topic>Metformin - therapeutic use</topic><topic>Middle Aged</topic><topic>pioglitazone</topic><topic>slowly progressive type 1 diabetes</topic><topic>Thiazolidinediones - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shimada, Akira</creatorcontrib><creatorcontrib>Shigihara, Toshikatsu</creatorcontrib><creatorcontrib>Okubo, Yoshiaki</creatorcontrib><creatorcontrib>Katsuki, Takeshi</creatorcontrib><creatorcontrib>Yamada, Yoshifumi</creatorcontrib><creatorcontrib>Oikawa, Yoichi</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes/metabolism research and reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shimada, Akira</au><au>Shigihara, Toshikatsu</au><au>Okubo, Yoshiaki</au><au>Katsuki, Takeshi</au><au>Yamada, Yoshifumi</au><au>Oikawa, Yoichi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pioglitazone may accelerate disease course of slowly progressive type 1 diabetes</atitle><jtitle>Diabetes/metabolism research and reviews</jtitle><addtitle>Diabetes Metab. Res. Rev</addtitle><date>2011-11</date><risdate>2011</risdate><volume>27</volume><issue>8</issue><spage>951</spage><epage>953</epage><pages>951-953</pages><issn>1520-7552</issn><eissn>1520-7560</eissn><coden>DMRRFM</coden><abstract>Background
It has been reported that intervention with insulin in slowly progressive type 1 diabetic (SPIDDM) patients delays the progression to an insulin‐dependent state compared to that with sulfonylureas. However, the rate of progression to SPIDDM with the use of insulin‐sensitizing agents is unknown. The aim of this study was to determine the effect of insulin‐sensitizing agents on SPIDDM patients.
Methods
The enrolled SPIDDM patients were randomly allocated to a pioglitazone or metformin group. When the haemoglobin A1C level was more than 8% on two consecutive occasions, the case was considered to reach the end point.
Results
By 4 years post‐intervention, all patients had reached the end point in the pioglitazone group, whereas only 20% of patients had reached the end point in the metformin group (p < 0.05).
Conclusions
Pioglitazone may accelerate the disease course of SPIDDM. Copyright © 2011 John Wiley & Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><pmid>22069291</pmid><doi>10.1002/dmrr.1235</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1520-7552 |
| ispartof | Diabetes/metabolism research and reviews, 2011-11, Vol.27 (8), p.951-953 |
| issn | 1520-7552 1520-7560 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_903148493 |
| source | Wiley Online Library - AutoHoldings Journals; MEDLINE |
| subjects | Adult Age of Onset Diabetes Mellitus, Type 1 - drug therapy Disease Progression Female Glycated Hemoglobin A - metabolism Humans Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Male metformin Metformin - therapeutic use Middle Aged pioglitazone slowly progressive type 1 diabetes Thiazolidinediones - adverse effects |
| title | Pioglitazone may accelerate disease course of slowly progressive type 1 diabetes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T03%3A54%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pioglitazone%20may%20accelerate%20disease%20course%20of%20slowly%20progressive%20type%201%20diabetes&rft.jtitle=Diabetes/metabolism%20research%20and%20reviews&rft.au=Shimada,%20Akira&rft.date=2011-11&rft.volume=27&rft.issue=8&rft.spage=951&rft.epage=953&rft.pages=951-953&rft.issn=1520-7552&rft.eissn=1520-7560&rft.coden=DMRRFM&rft_id=info:doi/10.1002/dmrr.1235&rft_dat=%3Cproquest_cross%3E903148493%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1767615508&rft_id=info:pmid/22069291&rfr_iscdi=true |